Brainalyze

Brainalyze is at the forefront of revolutionizing dementia treatment and care, pioneering innovative solutions in medical and diagnostic laboratories. With a vision to establish the first global dementia screening program, Brainalyze offers a breakthrough blood test capable of detecting and distinguishing multiple forms of dementia at an early stage. The primary address is University Road, Southampton, SO17 1BJ, GB; the company also has a presence in San Francisco, US.

Utilizing the proprietary MX-Raman™ platform, Brainalyze combines optical fingerprinting with interpretable AI to create an efficient and versatile diagnostic tool. This technology enables broad-spectrum dementia detection and differentiation through a rapid, cost-effective, and scalable testing process. Brainalyze is committed to enhancing early screening, patient triage, differential diagnosis, treatment monitoring, and clinical trial stratification.

Brainalyze's dedication to innovation is reflected in its patent-pending technology and extensive research. The company's unique approach goes beyond traditional biomarkers, offering a simple, single-step test that delivers fast and accurate results. Brainalyze is poised to transform the landscape of dementia diagnostics and contribute significantly to improved patient care worldwide. We invite the company’s management to create a customized and exclusive company showcase and product listing on our platform.